The changing face of renal cell carcinoma pathology

Aydın, Hakan; Zhou, Ming

doi:10.1007/s11912-008-0036-5

Cited by 6 publications

(7 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Alterations in chromosome 3p have been detected in the vast majority of sporadic clear cell RCC, many of which involve the Von Hippel-Lindau (VHL) tumor suppressor gene. 32 Whether or not clear cell histology portends a worse outcome than other histological subtypes has been controversial, although there is mounting evidence that clear cell carcinomas are more aggressive. [33][34][35] In a recent study from the Mayo Clinic, clear cell carcinoma subtype was an independent predictor of metastasis and cancer specific death as compared with papillary and chromophobe tumors, even after adjusting for other clinicopathological features.…”

Section: Sizementioning

confidence: 99%

Prognostic variables and nomograms for renal cell carcinoma

2010

View full text Add to dashboard Cite

Abstract:The term renal cell carcinoma (RCC) is used to describe a heterogeneous group of tumors that vary histologically, genetically and molecularly. Extensive research has been conducted to identify characteristics that predict outcomes among patients with RCC. In addition to histological subtype these include tumor size, patient age, mode of presentation and various hematological indices, among others. Several groups have incorporated these clinical and pathological features into nomograms which help the clinician better define individual patient prognosis and direct the optimum therapeutic approach. In the present article we review these prognostic variables and nomograms for RCC.

show abstract

Section: Sizementioning

confidence: 99%

Prognostic variables and nomograms for renal cell carcinoma

2010

View full text Add to dashboard Cite

show abstract

“…At best, limited information is available regarding the prognostic value of biomarkers in the context of papillary or chromophobe RCC – the data from ccRCC cannot be extrapolated to these other variants as they are biologically dissimilar. [78] The evaluation of biomarkers is predominantly semiquantitative and can be subject to observer bias. The determination of cutoff point for clinical significance is sometimes arbitrary and can alter the prognostic significance in the final analysis.…”

Section: Limitations Of Molecular Profiling Of Rccmentioning

confidence: 99%

“…It is well known that RCCs are comprised of pathologically and genetically diverse population of cancers. [78] This implies that regardless of tumor size and histology, the molecular attributes of a RCC can determine its risk of recurrence and metastasis. Therefore, characterizing the molecular biology of a tumor can provide vital information to the surgeon to help stratify risk and thereby guide therapy.…”

Section: Introductionmentioning

confidence: 99%

Molecular profiling of small renal masses: Current status and future directions

2009

View full text Add to dashboard Cite

Small renal masses (SRMs) are renal tumors less than 4 cm in diameter. These account for the largest proportion of newly diagnosed renal cell cancers (RCC). Management of SRMs can be a dilemma if the patient is unfit to undergo partial nephrectomy. Molecular profiling enables better characterization of RCC and prediction of outcomes in terms of recurrence and progression. This article reviews the existing literature on molecular profiling of localized RCC, discusses limitations of molecular profiling, and presents the likely role that molecular profiling will play in guiding the treatment of SRMs.

show abstract

“…Renal cell carcinoma (RCC), which arises from renal tubular epithelial cells [1]–[2], accounts for approximately 90% of all renal malignancies [3]. It was estimated to be diagnosed in over 60,000 individuals in the United States in 2011 [4].…”

Section: Introductionmentioning

confidence: 99%

Fabrication of mAb G250-SPIO Molecular Magnetic Resonance Imaging Nanoprobe for the Specific Detection of Renal Cell Carcinoma In Vitro

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Molecular magnetic resonance imaging (mMRI) has been paid more and more attention for early diagnosis of cancer. A sensitive and specific mMRI probe plays the most important role in this technique. In this study, superparamagnetic iron oxide (SPIO) nanoparticles and mAb G250 were conjugated as mMRI probe for the detection of clear cell renal cell carcinoma (ccRCC) using 3.0-Tesla MRI in vitro. mAb G250 could specifically recognize carbonic anhydrase IX (CAIX) antigen overexpressed in ccRCC and the SPIO nanoparticles as MRI contrast agent presented excellent MRI response and good biocompatibility. The successful assembly of this nanoprobe was confirmed by UV-vis spectrum, FT-IR spectroscopy and DLS analysis. In vitro MRI study on ccRCC cells and control cells indicated that our fabricated mAb G250-SPIO nanoprobe could be used in the specific labeling of clear cell renal carcinoma cells successfully.

show abstract

The changing face of renal cell carcinoma pathology

Cited by 6 publications

References 88 publications

Prognostic variables and nomograms for renal cell carcinoma

Prognostic variables and nomograms for renal cell carcinoma

Molecular profiling of small renal masses: Current status and future directions

Fabrication of mAb G250-SPIO Molecular Magnetic Resonance Imaging Nanoprobe for the Specific Detection of Renal Cell Carcinoma In Vitro

Contact Info

Product

Resources

About